Authorized purpose: Post-processing of dynamic brain MRI to generate perfusion maps for trained-physician interpretation.
Clinical role
Post-processing perfusion analysis
Images and patients
MRI · Brain
Key limitation
Keep in mind: The baseline ACR card lists all scanner manufacturers. This does not establish interoperability with every present-day scanner, sequence or PACS version.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Post-processing of dynamic brain MRI to generate perfusion maps for trained-physician interpretation.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain Input: Dynamically acquired MRI datasets from existing MRI systems.
Who uses it?Intended users: Trained physician
What does the software produce?Output: Relative cerebral blood volume (rCBV), cerebral blood flow (CBF), mean transit time (MTT) and time-to-peak (TTP) maps; automatic contrast-leakage correction for rCBV, brain masking, normal-appearing white matter normalization and DICOM export to PACS.
What is its most important limitation?Key limitation: The baseline ACR card lists all scanner manufacturers. This does not establish interoperability with every present-day scanner, sequence or PACS version.
Clinical takeaway. Clinical role: Post-processing of dynamic brain MRI to generate perfusion maps for trained-physician interpretation.
Evidence takeaway. Evidence from the reviewed source record: K080762 describes nonclinical software verification and validation, with clinical testing listed as not applicable. The later glioma comparison below is family evidence, not a v1.0 validation claim.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Post-processing of dynamic brain MRI to generate perfusion maps for trained-physician interpretation.
Relative cerebral blood volume (rCBV), cerebral blood flow (CBF), mean transit time (MTT) and time-to-peak (TTP) maps; automatic contrast-leakage correction for rCBV, brain masking, normal-appearing white matter normalization and DICOM export to PACS.
The baseline ACR card lists all scanner manufacturers. This does not establish interoperability with every present-day scanner, sequence or PACS version.
Exact FDA submission
Checked 2026-09-05
Preserved baseline compatibility statement; current system compatibility requires confirmation.
K080762 describes nonclinical software verification and validation, with clinical testing listed as not applicable. The later glioma comparison below is family evidence, not a v1.0 validation claim.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
K080762 describes nonclinical software verification and validation, with clinical testing listed as not applicable. The later glioma comparison below is family evidence, not a v1.0 validation claim.
No exact-v1.0 clinical sensitivity estimate was established.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-05
No exact-v1.0 clinical specificity estimate was established.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K080762 software verification and validation
DesignNonclinical software testing summarized for substantial equivalence
PopulationSoftware and perfusion-processing verification; no clinical cohort specified
Comparison of DSC-MRI Postprocessing Techniques in Predicting Microvascular Histology in Patients with Glioma
DesignClinical comparison of IB Neuro and nordicICE DSC-MRI postprocessing with histologic subanalyses
Population52 glioma patients with 3 T DSC imaging; subanalyses included 25 recurrent glioblastoma patients and 29 biopsies from 12 patients
Scopeproduct family
Tested versionIB Neuro; release not identified in the reviewed abstract
Samplen=52
IndependenceIndependence not established
PMID:26359151 · DOI:10.3174/ajnr.A4451
Preload and non-preload analyses and histologic correlations are contextual; subgroup denominators are not a pooled independent cohort and no v1.0 diagnostic metric is inferred.
Service-level context only: the vendor page for IB Neuro says some institutions use CPT 76498 (unlisted MRI procedure) for advanced quantitative and perfusion MRI analyses performed with IB Neuro, and notes AMA Category III codes 0865T and +0866T (effective 2024-01-01) for quantitative brain MRI analysis. The page does not state that any payer covers or pays for IB Neuro and gives no amount.
Product family
Checked 2026-10-26
Vendor page read 2026-10-26. It names IB Neuro without a version, so it is applied as product-family context to this version 1.0 entry. Eligibility depends on payer policy, site of service and documentation.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Dynamically acquired MRI datasets from existing MRI systems.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Exports perfusion parameter maps as DICOM images to PACS for later viewing; supports interactive voxel time curves and arterial-input-function selection.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The summary describes an OsiriX plug-in and a platform-independent base library for incorporation into viewing, CAD or PACS applications.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Relative cerebral blood volume (rCBV), cerebral blood flow (CBF), mean transit time (MTT) and time-to-peak (TTP) maps; automatic contrast-leakage correction for rCBV, brain masking, normal-appearing white matter normalization and DICOM export to PACS.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Relative cerebral blood volume (rCBV), cerebral blood flow (CBF), mean transit time (MTT) and time-to-peak (TTP) maps; automatic contrast-leakage correction for rCBV, brain masking, normal-appearing white matter normalization and DICOM export to PACS.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Exports perfusion parameter maps as DICOM images to PACS for later viewing; supports interactive voxel time curves and arterial-input-function selection.
The 510(k) summary states that the generated parametric perfusion maps, when interpreted by a trained physician, may yield information useful in the assessment of the patient.
Exact FDA submission
Checked 2026-10-27
User qualification wording only; the summary specifies no training program or training offering for this device.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-05Last searched
19Fields reviewed
11Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
Stored metadata screened and primary abstract reviewed. Relevant IB Neuro glioma study retained as product-family context; no exact v1.0 linkage or product-wide numeric accuracy claim. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, acr ai central product, fda decision summary, vendor product page, peer reviewed literature, stored candidate metadata, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Care setting: Not publicly available - checked 2026-09-05 - Exact FDA submission
A specific care setting and age restriction were not established in the reviewed v1.0 summary.
Public pricing: Not verified - checked 2026-09-05 - Exact FDA submission
The reviewed current product page does not establish a v1.0 license, support or upgrade price.
Pricing model: Not verified - checked 2026-09-05 - Exact FDA submission
Legacy and current product licensing terms may differ; no pricing model is established.
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-05 - Exact FDA submission
The 2008 summary does not establish current host security, patch support or a scoped certification for v1.0.
Installation timeline: Not yet reviewed
Monitoring: Not verified - checked 2026-09-05 - Exact FDA submission
Current maintenance and clinical monitoring arrangements for the legacy release were not established.
Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.
Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.
Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.
Authorized purpose: Swoop Portable MR Imaging System provides ultra-low-field point-of-care head MRI for all ages and includes deep-learning T1, T2, FLAIR, and DWI reconstruction.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.